SCHEMBL16648570

SCHEMBL16648570

CCOC(=O)C1CCN(c2ncccc2Cl)CC1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.64
CYP2C19 P33261 1/20 0.63
MALT1 Q9UDY8 6/20 0.57
ALDH1A1 P00352 3/20 0.56
KMT2A Q03164 2/20 0.56
MEN1 O00255 1/20 0.56
POLB P06746 1/20 0.54
CTSB P07858 1/20 0.54
TRPV1 Q8NER1 1/20 0.54
TSHR P16473 3/20 0.53
GAA P10253 2/20 0.53
KDM4E B2RXH2 3/20 0.53
ALOX12 P18054 2/20 0.53
TP53 P04637 1/20 0.53
NFKB1 P19838 1/20 0.53
NFKB2 Q00653 1/20 0.53
RELA Q04206 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
SMN1; SMN2 Q16637 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3594750 0.89 MAPT (0.59) MAPTCYP2C19MALT1ALDH1A1KMT2A
SCHEMBL3435703 0.86 MAPT (0.57) MAPTCYP2C19MALT1ALDH1A1KMT2A
SCHEMBL2425939 0.86 MALT1 (0.64) MALT1KMT2AMEN1TRPV1KDM4E
SCHEMBL4865937 0.84 RORC (0.55) MAPTCYP2C19MALT1ALDH1A1KMT2A
SCHEMBL14338319 0.84 CYP2C19 (0.48) MAPTCYP2C19MALT1ALDH1A1KMT2A
SCHEMBL1253240 0.83 ALDH1A1 (0.59) MAPTCYP2C19MALT1ALDH1A1CTSB
SCHEMBL4255322 0.82 CTSB (0.68) MAPTCYP2C19ALDH1A1KMT2ACTSB
SCHEMBL3436721 0.82 ALOX15 (0.58) MAPTCYP2C19ALDH1A1KMT2APOLB
SCHEMBL16769731 0.81 MALT1 (0.64) MALT1KMT2ATRPV1
SCHEMBL195417 0.81 KDM4E (0.60) MAPTCYP2C19ALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2862861-B1 PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2016-01-06 EP disclosed
EP-2862861-B1 PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2016-01-06 EP disclosed
US-9150575-B2 Piperidinylpyrazolopyridine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-10-06 US disclosed
US-9150575-B2 Piperidinylpyrazolopyridine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-10-06 US disclosed
US-20150152102-A1 PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-06-04 US disclosed
US-20150152102-A1 PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-06-04 US disclosed
EP-2862861-A1 PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-04-22 EP disclosed
EP-2862861-A1 PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-04-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150152102-A1 PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE LCAT, LPL, LCLAT1 MAPT 1111/4885CYP2C19 3047/4885MALT1 4756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.